Exhibit 99.1
FOR IMMEDIATE RELEASE
|
| CONTACT: |
|
| Benjamin K. Stephen |
| Director, Investor Relations |
| 703-904-5539 |
| bstephen@quadramed.com |
|
| David L. Piazza |
| Vice President, Finance |
| 703-742-5312 |
| dpiazza@quadramed.com |
QUADRAMED ANNOUNCES COMPLETION OF TENDER OFFER
FOR 10% SENIOR NOTES DUE 2008
Reston, VA – July 20, 2004
QuadraMed Corporation (QMDC.OB) announced today that its previously announced cash tender offer to purchase any and all of its outstanding 10% Senior Secured Notes due 2008 (the “Notes”) expired as of 5:00 p.m. EDT, on Friday, July 16, 2004. All of the Notes were purchased; for an aggregate purchase price including accrued and unpaid interest of approximately $79.3 million.
About QuadraMed Corporation
QuadraMed is dedicated to improving healthcare delivery by providing innovative healthcare information technology and services. From clinical and patient information management to revenue cycle and health information management, QuadraMed delivers real-world solutions that help healthcare professionals deliver outstanding patient care with optimum efficiency. Behind our products and services is a staff of more than 850 professionals whose experience and dedication to service has earned QuadraMed the trust and loyalty of customers at more than 1,900 healthcare provider facilities. To find out more about QuadraMed, visit www.quadramed.com.
Cautionary Statement on Risks Associated with QuadraMed’s Forward-Looking Statements
This press release contains forward-looking statements by QuadraMed as defined by the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. The words “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “may,” “should,” “could,” and similar expressions are intended to identify such statements. Forward-looking statements are not guarantees of future performance and are to be interpreted only as of the date on which they are made. QuadraMed undertakes no obligation to update or revise any forward-looking statement except as required by law. QuadraMed advises investors that it discusses risk factors and uncertainties that could cause QuadraMed’s actual results to differ from forward-looking statements in its periodic reports filed with the Securities and Exchange Commission (“SEC”).
QuadraMed’s SEC filings can be accessed through the Investor Relations section of our website, www.quadramed.com, or through the SEC’s EDGAR Database atwww.sec.gov (QuadraMed has EDGAR CIK No. 0001018833).
Note to editors: QuadraMed is a registered trademark of QuadraMed Corporation. All other trademarks are the property of their respective owners.
###
